Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|September 1, 2017
Evolving Paradigms
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Advertisement
Articles in this issue
about 9 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCabout 9 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCabout 9 years ago
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Saysabout 9 years ago
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLCAdvertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5